Mechanistically, ketamine’s rapid antidepressant and anti-suicidal effects may involve direct opioid receptor signaling in adult MDD patients [90], whereas fluoxetine primarily modulates opioid function indirectly by altering MOR expression and responsiveness rather than through direct receptor binding [91]. The gene discussed is OPRM1; the disease is major depressive disorder.